Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.42 |
| ▸ | GOT1 | P17174 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146783 | 1.00 | PDE5A (0.42) | PDE5AGOT1LMNAKMT2AALDH1A1 | |
| SCHEMBL4125268 | 0.84 | PDE5A (0.40) | PDE5ALMNAKMT2AALDH1A1NR4A2 | |
| SCHEMBL31617120 | 0.84 | PDE5A (0.38) | PDE5ALMNAKMT2AALDH1A1GPR55 | |
| SCHEMBL10662227 | 0.78 | SMN1; SMN2 (0.58) | PDE5ALMNAKMT2AALDH1A1POLB | |
| SCHEMBL10960961 | 0.77 | PIK3CG (0.42) | LMNAKMT2AALDH1A1NR4A2POLB | |
| SCHEMBL2459267 | 0.75 | HTT (0.41) | GOT1LMNAKMT2AALDH1A1POLB | |
| SCHEMBL1102314 | 0.75 | ALDH1A1 (0.40) | GOT1LMNAKMT2AALDH1A1POLB | |
| SCHEMBL29426545 | 0.75 | HTT (0.41) | GOT1LMNAKMT2AALDH1A1POLB | |
| SCHEMBL2458924 | 0.75 | CYP3A4 (0.42) | GOT1LMNAKMT2AALDH1A1PARP1 | |
| SCHEMBL30040888 | 0.75 | LMNA (0.44) | GOT1LMNAKMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) | 2025-07-03 | — | — | US | disclosed |
| WO-2025119372-A2 | MRGPRX2 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-06-12 | — | — | WO | disclosed |
| EP-4559521-A2 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2025-05-28 | — | — | EP | disclosed |
| EP-4404931-B1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN (DE) | 2025-04-09 | — | — | EP | disclosed |
| EP-4458358-A1 | PYRIDAZINE COMPOUNDS FOR ANTIFIBROTIC THERAPY | Tietze Chemical Consulting UG (DE) | 2024-11-06 | — | — | EP | disclosed |
| EP-4404931-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023222865-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2023-11-23 | — | — | WO | disclosed |
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| EP-0722936-B1 | FUSED PYRIDAZINE COMPOUND | EISAI CO LTD (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6218392-B1 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, MYOCARDIAL INFARCT AND CHRONIC AND ACUTE CARDIAC FAILURE, PULMONARY HYPERTENSION, ARTERIOSCLEROSIS AND BRONCHIAL ASTHMA | EISAI CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-5849741-A | Fused pyridazine compounds | EISAI CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0722936-A1 | FUSED PYRIDAZINE COMPOUND | Eisai Co., Ltd. (JP) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | COL1A1, COL14A1, COL2A1 | PDE5A 806/4885GOT1 474/4885LMNA 1712/4885 |
| US-20100069368-A1 | Organic Compounds and Their Uses | SHH, GLI1, VHL | PDE5A 3978/4885GOT1 657/4885LMNA 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.